載入中
OmniAb, Inc. is an American biotechnology firm focused on pioneering therapeutic antibody discovery. The company provides a sophisticated platform that allows its industry partners to access a broad spectrum of antibody repertoires and advanced screening techniques, thereby facilitating the development of next-generation treatments. Central to the OmniAb platform is the unique biological capability of proprietary genetically engineered animals, such as OmniRat, OmniChicken, and OmniMouse. These animals are modified to produce human-sequence antibodies, simplifying the creation of human therapeutic candidates. Additionally, OmniAb offers specialized technologies like OmniFlic (a transgenic rat) and OmniClic (a transgenic chicken), which address the requirements for bispecific antibody applications via a common light chain method, as well as OmniTaur, which leverages the distinct structural properties of cow antibodies for challenging targets. The company was founded in 2012 and is based in Emeryville, California.
收盤時
US$4.77
−US$0.02 · -0.42%
盤後
US$4.77
US$0.00 · 0.00%
10月12日 下午4:10 ET
盤中時間採用ET。市場資料可能有所延遲。
OmniAb, Inc. is an American biotechnology firm focused on pioneering therapeutic antibody discovery. The company provides a sophisticated platform that allows its industry partners to access a broad spectrum of antibody repertoires and advanced screening techniques, thereby facilitating the development of next-generation treatments. Central to the OmniAb platform is the unique biological capability of proprietary genetically engineered animals, such as OmniRat, OmniChicken, and OmniMouse. These animals are modified to produce human-sequence antibodies, simplifying the creation of human therapeutic candidates. Additionally, OmniAb offers specialized technologies like OmniFlic (a transgenic rat) and OmniClic (a transgenic chicken), which address the requirements for bispecific antibody applications via a common light chain method, as well as OmniTaur, which leverages the distinct structural properties of cow antibodies for challenging targets. The company was founded in 2012 and is based in Emeryville, California.
日內區間
目前US$4.77
52週區間
目前US$4.77
盤中時間採用ET。市場資料可能有所延遲。
OmniAb, Inc. is an American biotechnology firm focused on pioneering therapeutic antibody discovery. The company provides a sophisticated platform that allows its industry partners to access a broad spectrum of antibody repertoires and advanced screening techniques, thereby facilitating the development of next-generation treatments. Central to the OmniAb platform is the unique biological capability of proprietary genetically engineered animals, such as OmniRat, OmniChicken, and OmniMouse. These animals are modified to produce human-sequence antibodies, simplifying the creation of human therapeutic candidates. Additionally, OmniAb offers specialized technologies like OmniFlic (a transgenic rat) and OmniClic (a transgenic chicken), which address the requirements for bispecific antibody applications via a common light chain method, as well as OmniTaur, which leverages the distinct structural properties of cow antibodies for challenging targets. The company was founded in 2012 and is based in Emeryville, California.
日內區間
目前US$4.77
52週區間
目前US$4.77
獲利能力占已公布營收的百分比。
營收
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | 1866.6萬 USD | 2639.1萬 USD | 3416.4萬 USD | 5907.7萬 USD | 3474.8萬 USD |
| 銷貨成本 | 2205.7萬 USD | — | — | — | — |
| 毛利 | −339.1萬 USD | 2639.1萬 USD | 3416.4萬 USD | 5907.7萬 USD | 3474.8萬 USD |
| 研究與開發 | 4775.4萬 USD | 5511萬 USD | 5652.5萬 USD | 4836.4萬 USD | 3923.2萬 USD |
| 銷售、一般及管理費用 | 2921.5萬 USD | 3074.1萬 USD | 3331.3萬 USD | 2490.3萬 USD | 1694.7萬 USD |
| 營業費用 | 6812.7萬 USD | 1.01億 USD | 1.04億 USD | 8572.5萬 USD | 7035.7萬 USD |
| 利息收入 | 266萬 USD | 310.6萬 USD | 505.5萬 USD | 58.7萬 USD | — |
| 利息支出 | — | — | — | — | 7000 USD |
| 折舊和攤銷 | 2175.4萬 USD | 2358.3萬 USD | 1949.7萬 USD | 1824.9萬 USD | 1625.2萬 USD |
| 營業利益 | −7151.8萬 USD | −7450.2萬 USD | −6941.9萬 USD | −2664.8萬 USD | −3560.9萬 USD |
| 淨利 | −6477.9萬 USD | −6203.3萬 USD | −5061.9萬 USD | −2233.4萬 USD | −2704.2萬 USD |
公司資料更新於 2026年10月12日。
近期已公布業績
近期已公布業績
第三方分析師預期可能變動，並非 GoAI 建議。
平均目標
US$4.00
下跌空間 16.14%價格歷史記錄不可用
最高：US$4.00平均的：US$4.00最低：US$4.00報告持有此股票曝險的交易所交易基金。
iShares Russell 2000 ETFIWM1381.59萬0.02%787.4億 USD0.19%US$277.88-0.38%
Vanguard Morningstar Total Stock Market ETFVTI1042.32萬0.00%2.3兆 USD0.03%US$381.57-0.10%
Vanguard Extended Market ETFVXF611.98萬0.01%954億 USD0.05%US$233.52-0.63%
iShares Biotechnology ETFIBB446.63萬0.04%108.2億 USD0.44%US$204.26-1.08%
Schwab U.S. Small-Cap ETFSCHA280.48萬0.01%218.24億 USD0.03%US$32.66-0.40%
Vanguard Russell 2000 ETFVTWO277.02萬0.02%180億 USD0.06%US$112.27-0.35%
iShares Micro-Cap ETFIWC166.4萬0.13%13.17億 USD0.60%US$181.66-0.73%
Dimensional - US Small Cap ETFDFAS152.71萬0.00%338.69億 USD0.31%US$78.17-0.23%iShares Russell 2000 ETFIWMVanguard Morningstar Total Stock Market ETFVTIVanguard Extended Market ETFVXFiShares Biotechnology ETFIBBSchwab U.S. Small-Cap ETFSCHAVanguard Russell 2000 ETFVTWOiShares Micro-Cap ETFIWCDimensional - US Small Cap ETFDFASAI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
